bleomycetin profile

bleomycetin: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	13258907
MeSH ID	M0085400

Synonym
bleomycetin

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
" We evaluated our experience to present a safe treatment method for venous malformations."	( Sclerotherapy after embolization of draining vein: a safe treatment method for venous malformations. Hu, X; Jin, Y; Li, W; Lin, X; Ma, G; Wang, W, 2008)	0.35
"Percutaneous sclerotherapy of venous malformations using absolute ethanol and bleomycin A5 is safe and effective."	( Sclerotherapy after embolization of draining vein: a safe treatment method for venous malformations. Hu, X; Jin, Y; Li, W; Lin, X; Ma, G; Wang, W, 2008)	0.35
"The results suggested that intralesional injection of pingyangmycin is an effective and safe treatment for microcystic LMs in the tongue, and can be used as the first-line treatment protocol."	( Intralesional injection of pingyangmycin is a safe and effective treatment for microcystic lymphatic malformations in the tongue. Fan, XD; Mai, HM; Wang, YA; Yang, XJ; Zheng, JW; Zhou, Q, 2013)	0.39
" Intralesional injection of high concentration of bleomycin A5 was an effective and safe treatment of huge macrocystic LMs in the cervical region and can obtain satisfactory results esthetically and functionally without surgery."	( Appraisal of efficacy and safety of intralesional injection of high concentration of bleomycin A5 for treatment of huge macrocystic lymphatic malformations in cervical region. Cheng, C; Gong, H; Wang, HW; Wang, XK; Xu, DP; Zhai, QK, 2014)	0.4
" Chemotherapy-related adverse events were routinely monitored."	( Safety and efficacy of bleomycin/pingyangmycin-containing chemotherapy regimens for malignant germ cell tumor patients in the female genital system. Cao, D; Han, J; Lang, J; Liu, Y; Pan, L; Shen, K; Wu, M; Xiang, Y; Xu, K; Yang, J; Yu, M; Zhao, Q, 2017)	0.46
" A meta-analysis on the risk of adverse events (AEs) showed a lower risk for polidocanol versus other treatments, for example, all the conventional treatments used independently (p < ."	( Effectiveness and safety of polidocanol for the treatment of hemangiomas and vascular malformations: A meta-analysis. Gao, Z; Li, W; Shi, C; Zhang, Y, 2018)	0.48
" No statistical difference was observed between groups in the incidence of adverse reactions."	( Clinical Efficacy and Safety of Pulsed Dye Laser Combined with Pingyangmycin on Hyperplastic Scar after Acne. Guo, R; He, X; Xu, K; Xuan, W, 2022)	0.72

Compound-Compound Interactions

Excerpt	Reference	Relevance
"To observe the outcome of using fibrin glue (FG) combined with Pingyangmycin (Tianjin Taihe Pharmaceutical Co Ltd, Tianjin, China) in the treatment of venous malformations (VMs) in the oral and maxillofacial region."	( Preliminary study of fibrin glue combined with pingyangmycin for the treatment of venous malformations in the oral and maxillofacial region. Cheng, X; Hou, R; Lei, D; Liu, Y; Sun, M; Wang, L; Yan, Z; Yang, Y, 2008)	0.35
" All these patients were injected with FG combined with Pingyangmycin."	( Preliminary study of fibrin glue combined with pingyangmycin for the treatment of venous malformations in the oral and maxillofacial region. Cheng, X; Hou, R; Lei, D; Liu, Y; Sun, M; Wang, L; Yan, Z; Yang, Y, 2008)	0.35
"The therapeutic modality of FG combined with Pingyangmycin for VMs in the oral and maxillofacial region was effective, and the extent of morbidity was acceptable."	( Preliminary study of fibrin glue combined with pingyangmycin for the treatment of venous malformations in the oral and maxillofacial region. Cheng, X; Hou, R; Lei, D; Liu, Y; Sun, M; Wang, L; Yan, Z; Yang, Y, 2008)	0.35
" The purpose of this study was to evaluate the clinical curative effect of percutaneous sclerotherapy of massive venous malformations of the face and neck using fibrin glue combined with OK-432 and pingyangmycin."	( Percutaneous sclerotherapy of massive venous malformations of the face and neck using fibrin glue combined with OK-432 and pingyangmycin. Chai, Q; Chen, WL; Huang, ZQ; Zhang, DM, 2010)	0.36
"Eighteen patients with massive venous malformations were treated with an injection of fibrin glue combined with OK-432 and pingyangmycin."	( Percutaneous sclerotherapy of massive venous malformations of the face and neck using fibrin glue combined with OK-432 and pingyangmycin. Chai, Q; Chen, WL; Huang, ZQ; Zhang, DM, 2010)	0.36
"Percutaneous sclerotherapy using fibrin glue combined with OK-432 and pingyangmycin provided a simple, safe, and reliable alternative treatment for massive venous malformations."	( Percutaneous sclerotherapy of massive venous malformations of the face and neck using fibrin glue combined with OK-432 and pingyangmycin. Chai, Q; Chen, WL; Huang, ZQ; Zhang, DM, 2010)	0.36
"To evaluate the therapeutic effect of retained copper wires combined with pingyangmycin (PYM) injection for complicated cavernous venous malformation."	( [Treatment of complicated cavernous venous malformation with retained copper wires combined with pingyangmycin injection]. Hong, ZJ; Hu, XB; Jiang, HQ; Wang, J; Wang, XK; Yuan, SM, 2009)	0.35
"It is very effective to treat complicated cavernous venous malformation with retained copper wires combined with pingyangmycin injection."	( [Treatment of complicated cavernous venous malformation with retained copper wires combined with pingyangmycin injection]. Hong, ZJ; Hu, XB; Jiang, HQ; Wang, J; Wang, XK; Yuan, SM, 2009)	0.35
"To investigate the clinical effect of electrochemical therapy (ECT) combined with pingyangmycin (PYM) injection for the treatment of high-return flow venous malformation."	( [Electrochemical therapy combined with pingyangmycin injection in the management of high-return flow venous malformation]. Jin, ZL; Li, QJ; Wang, XK; Wei, JJ; Xue, L; Yuan, WL, 2012)	0.38
"A total of 68 cases of the high-return flow venous malformation were retrospectively analyzed, in which 32 cases received simplely ECT,and 36 cases received ECT combined with PYM injection."	( [Electrochemical therapy combined with pingyangmycin injection in the management of high-return flow venous malformation]. Jin, ZL; Li, QJ; Wang, XK; Wei, JJ; Xue, L; Yuan, WL, 2012)	0.38
"The effectiveness of ECT was 78% (25/32), and of ECT combined with PYM injection was 97% (35/36)."	( [Electrochemical therapy combined with pingyangmycin injection in the management of high-return flow venous malformation]. Jin, ZL; Li, QJ; Wang, XK; Wei, JJ; Xue, L; Yuan, WL, 2012)	0.38
"ECT combined with PYM injection is an effective method for the treatment of high-return flow venous malformation."	( [Electrochemical therapy combined with pingyangmycin injection in the management of high-return flow venous malformation]. Jin, ZL; Li, QJ; Wang, XK; Wei, JJ; Xue, L; Yuan, WL, 2012)	0.38
"To review our experience with the use of the CO2 laser combined with pingyangmycin in the treatment of pharyngeal and laryngeal hemangioma."	( [The application of the CO2 laser combined with pingyangmycin in the management of pharyngeal and laryngeal hemangioma]. Deng, R; Hua, Q; Qu, J; Tao, Z; Wang, Y, 2013)	0.39
"A retrospective review of 18 patients with pharyngeal and laryngeal hemangioma treated with CO2 laser combined with pingyangmycin was carried out in our hospital: patients medical charts were evaluated for factors such as age, sex, location of hemangioma, number of laser procedures performed, and postoperative results, including short and long term complications."	( [The application of the CO2 laser combined with pingyangmycin in the management of pharyngeal and laryngeal hemangioma]. Deng, R; Hua, Q; Qu, J; Tao, Z; Wang, Y, 2013)	0.39
"With careful selection of patients, the CO2 laser combined with pingyangmycin pingyangmycin is a safe and effective treatment for pharyngeal and laryngeal hemangioma with the following advantages: precise location for treating, less bleeding, clear operating field, simple management, low risk of infection, less post-operation reaction, protection of laryngeal and pharyngeal structures and avoidance of tracheostomy."	( [The application of the CO2 laser combined with pingyangmycin in the management of pharyngeal and laryngeal hemangioma]. Deng, R; Hua, Q; Qu, J; Tao, Z; Wang, Y, 2013)	0.39
" To evaluate the therapeutic effects of nanosecond pulsed electric field (nsPEF) combined with pingyangmycin (PYM) on salivary gland adenoid cystic carcinoma (SACC), ACC high metastatic cell line (SACC-LM) and low metastatic cell line (SACC‑83) were tested by CCK-8 assay, cell clonogenic assay, flow cytometry and Transwell assay."	( Synergistic effect of nanosecond pulsed electric field combined with low-dose of pingyangmycin on salivary adenoid cystic carcinoma. Guo, J; Pan, J; Qi, W; Su, B; Wu, S; Zhang, J; Zhang, L, 2014)	0.4
"The purpose of the article was to assess the clinical results of mattress cerclage combined with electrochemical therapy and pingyangmycin injection after embolization in treating arteriovenous malformations (AVMs)."	( Mattress cerclage combined with electrochemical therapy and pingyangmycin injection after embolization for management of arteriovenous malformation on oral and maxillofacial region. Cheng, C; Gong, H; Wang, XK; Xi, SL; Xu, DP; Zhai, QK, 2015)	0.42
"During the period from January 2008 to December 2012, a total of 26 patients with AVMs were treated through mattress cerclage combined with electrochemical therapy and pingyangmycin injection after embolization and were retrospectively examined."	( Mattress cerclage combined with electrochemical therapy and pingyangmycin injection after embolization for management of arteriovenous malformation on oral and maxillofacial region. Cheng, C; Gong, H; Wang, XK; Xi, SL; Xu, DP; Zhai, QK, 2015)	0.42
"Mattress cerclage combined with electrochemical therapy and pingyangmycin injection after embolization was a reliable method for AVMs."	( Mattress cerclage combined with electrochemical therapy and pingyangmycin injection after embolization for management of arteriovenous malformation on oral and maxillofacial region. Cheng, C; Gong, H; Wang, XK; Xi, SL; Xu, DP; Zhai, QK, 2015)	0.42
"The aim of the present study was to evaluate the therapeutic outcome of using electrochemical therapy (ECT) combined with a sclerosing agent, pingyangmycin (bleomycin A5 hydrochloride; PYM), for large (>3 cm in diameter) venous malformations (VMs) in the oral and maxillofacial regions."	( Percutaneous Treatment of Large Venous Malformations in the Oral and Maxillofacial Regions Using Electrochemical Therapy Combined With Pingyangmycin. Cao, RY; Sun, NN; Tan, HS; Wang, XK; Xu, DP; Xue, L, 2015)	0.42
"To evaluate the effect of bleomyin A5 combined with phosphorus-32 colloid in the treatment of mucocele."	( [A clinical study on the treatment of mucocele by bleomyin A5 combined with phosphorus-32 colloid]. Chen, X; Guo, F; Hu, J; Liu, J; Pang, X; Wang, X, 2015)	0.42
"A total of 214 patients divided into three groups, bleomyin A5 (50 cases), phosphorus-32 colloid (50 cases) and bleomyin A5 combined with phosphorus-32 colloid (114 cases)."	( [A clinical study on the treatment of mucocele by bleomyin A5 combined with phosphorus-32 colloid]. Chen, X; Guo, F; Hu, J; Liu, J; Pang, X; Wang, X, 2015)	0.42
"The efficacy of bleomyin A5 group, phosphorus-32 colloid group, and bleomyin A5 combined with phosphorus-32 colloid group was 84% (42/50), 82% (41/50) and 98% (112/114), respectively."	( [A clinical study on the treatment of mucocele by bleomyin A5 combined with phosphorus-32 colloid]. Chen, X; Guo, F; Hu, J; Liu, J; Pang, X; Wang, X, 2015)	0.42
"To compare the clinical efficacy of pingyangmycin and lauromacrogol combined with pingyangmycin in the treatment of venous malformations (VMs)."	( [Clinical efficacy of lauromacrogol combined with pingyangmycin in the treatment of venous malformation: clinical analysis of 120 consecutive cases]. Cai, Y; Liu, DX; Liu, L; Zhao, JH; Zhong, HY, 2016)	0.43
"One hundred and twenty patients with VM were randomly divided into lauromacrogol combined with pingyangmycin injection group (experimental group) and pingyangmycin injection group (control group)."	( [Clinical efficacy of lauromacrogol combined with pingyangmycin in the treatment of venous malformation: clinical analysis of 120 consecutive cases]. Cai, Y; Liu, DX; Liu, L; Zhao, JH; Zhong, HY, 2016)	0.43
"Compared to the single use of pingyangmycin, lauromacrogol combined with pingyangmycin is more effective for the treatment of VM, with fewer sessions required and no adverse effects."	( [Clinical efficacy of lauromacrogol combined with pingyangmycin in the treatment of venous malformation: clinical analysis of 120 consecutive cases]. Cai, Y; Liu, DX; Liu, L; Zhao, JH; Zhong, HY, 2016)	0.43
"To investigate the clinical effect of radiofrequency ablation (RFA) combined with lauromacrogol for the treatment of parotid gland hemangioma in infants."	( [Clinical study of radiofrequency ablation combined with lauromacrogol for the treatment of parotid gland hemangioma in infants]. Chen, H; Chen, J; Cui, J; Han, T; Ji, Y; Shen, W; Zou, J, 2016)	0.43
"The observation group was treated by RFA combined with lauromacrogol, while the control group 1 was treated by RFA only, the control group 2 was treated by pingyangmycin only, and the control group 3 received additional pingyangmycin based on RFA."	( [Clinical study of radiofrequency ablation combined with lauromacrogol for the treatment of parotid gland hemangioma in infants]. Chen, H; Chen, J; Cui, J; Han, T; Ji, Y; Shen, W; Zou, J, 2016)	0.43
"The objectives of this study were to document the results of using fibrin glue (FG) combined with pingyangmycin (PYM) for the embolism and sclerotherapy of maxillofacial arteriovenous malformations (AVMs)."	( Embolization and sclerotherapy of maxillofacial arteriovenous malformations with the use of fibrin glue combined with pingyangmycin. Sun, M; Wang, W; Wei, J; Wu, W; Yan, Z; Yang, X; Yang, Y, 2020)	0.56
" The major treatment method was direct percutaneous puncture and injection of FG combined with PYM."	( Embolization and sclerotherapy of maxillofacial arteriovenous malformations with the use of fibrin glue combined with pingyangmycin. Sun, M; Wang, W; Wei, J; Wu, W; Yan, Z; Yang, X; Yang, Y, 2020)	0.56
"These data suggest that embolization and sclerotherapy with the use of FG combined with PYM are safe and effective for the treatment of small- to medium-sized, locally dilated maxillofacial AVMs."	( Embolization and sclerotherapy of maxillofacial arteriovenous malformations with the use of fibrin glue combined with pingyangmycin. Sun, M; Wang, W; Wei, J; Wu, W; Yan, Z; Yang, X; Yang, Y, 2020)	0.56
"This research analyzed the clinical effectiveness and safety of pulsed dye laser (PDL) combined with pingyangmycin (PI) in the treatment of post-acne HS."	( Clinical Efficacy and Safety of Pulsed Dye Laser Combined with Pingyangmycin on Hyperplastic Scar after Acne. Guo, R; He, X; Xu, K; Xuan, W, 2022)	0.72
"PDL combined with PI can effectively improve the clinical efficacy, scar repair effect, overall skin status, and treatment experience of patients and boost the psychological state and prognostic quality of life of patients, which has great clinical application prospect for the treatment of HS."	( Clinical Efficacy and Safety of Pulsed Dye Laser Combined with Pingyangmycin on Hyperplastic Scar after Acne. Guo, R; He, X; Xu, K; Xuan, W, 2022)	0.72

Bioavailability

Excerpt	Reference	Relevance
" Experiments performed by artery perfusion and embolization in rabbits central auricular artery revealed that the PYM loaded BSA-MSs (PYM-BSA-MSs) could obviously prolong in vivo drug release, extend the mean residence time (MRT) and had equal bioavailability compared with plain PYM injections."	( Preparation and characterization of Pingyangmycin-loaded bovine serum albumin microspheres for embolization therapy. Bi, Y; Gan, L; Gao, Q; Hou, S; Liu, J; Wang, C; Wang, X, 2007)	0.34

Dosage Studied

Subcutaneous implantation of the new dosage form of bleomycetin with prolonged action provided a significant antitumor systemic effect evident from an increase in the mouse life-span.

Excerpt	Relevance	Reference
" The dosage of bleomycin A5 was 10 mg per time."	( [Local injection of bleomycin A5 in lymphangioma in children. Analysis of 100 cases]. Jiang, JP, 1989)	0.28
" Subcutaneous implantation of the new dosage form of bleomycetin with prolonged action provided a significant antitumor systemic effect evident from an increase in the mouse life-span."	( [An in vivo experiment on the antitumor action of bleomycin bound to an ion exchange carrier]. Bukhman, VM; Filippos'iants, ST; Prigozhina, MM; Tikhomirov, GA, 1994)	0.29
"Possible local application of a new dosage form of bleomycetin (bleomycin) with the prolonged action was studied in experimental in vivo models."	( [Effectiveness of local in vivo application of bleomycetin (bleomycin), chemosorbed on ion exchange medical gauze]. Bukhman, VM; Filatov, VN; Prigozhina, MM; Ryltsev, VV; Tikhomirov, GA, 1995)	0.29
" This was to study the signal transduction pathways that might exert the apoptotic effects of bleomycin A5 on tumor cells, as well as to examine the possibility of lower dosing of such drug in combinative treatment with other compounds in vitro."	( MEK inhibition enhances bleomycin A5-induced apoptosis in an oral cancer cell line: signaling mechanisms and therapeutic opportunities. Chou, MY; Tai, KW; Yang, JJ; Yang, LC; Yang, SH, 2004)	0.32
" The drug was given by multiple intralesional injections, with the dosage calculated according to the age of the patient and size of the lesion."	( How to use bleomycin A5 for infantile maxillofacial haemangiomas: clinical evaluation of 82 consecutive cases. Luo, Q; Zhao, F, 2011)	0.37
"Bleomycin A5 was given by multiple intralesinoal injections and the dosage was given according to the age of the patient and size of the lesion."	( The effects of Bleomycin A5 on infantile maxillofacial haemangioma. Luo, QF; Zhao, FY, 2011)	0.37
"PYM-CH-NP can increase drug dosage in metastasized cervical lymph nodes, and decrease drug dosage of other organs."	( [Lymphatic targeting study of pingyangmycin-activated carbon nanoparticles treating oral cancer lymph node metastasis]. Sun, ML; Wang, CM; Wen, YM; Xie, WH, 2011)	0.37
" Histopathological observations revealed no noticeable toxico-pathological changes in the lung and various organs, indicating that the PYM and anti-PD-1 antibody combination exerted enhanced efficacy at well-tolerated dosage level."	( Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8 Du, YB; Ge, ZJ; Gong, JH; Li, Y; Liu, XJ; Shan, CK; Wang, YX; Zhai, XT; Zhen, YS, 2021)	0.62

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	31 (12.16)	18.7374
1990's	30 (11.76)	18.2507
2000's	77 (30.20)	29.6817
2010's	102 (40.00)	24.3611
2020's	15 (5.88)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	30 (11.28%)	5.53%
Reviews	5 (1.88%)	6.00%
Case Studies	11 (4.14%)	4.05%
Observational	1 (0.38%)	0.25%
Other	219 (82.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
carnitine [no description available]	3.15	1	0	amino-acid betaine	human metabolite; mouse metabolite
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	2.05	1	0	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
formaldehyde paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy	2.03	1	0	aldehyde; one-carbon compound	allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
alpha-glycerophosphoric acid [no description available]	2.17	1	0	glycerol monophosphate	algal metabolite; human metabolite
spermidine [no description available]	2.68	3	0	polyazaalkane; triamine	autophagy inducer; fundamental metabolite; geroprotector
urea pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.	2.11	1	0	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
1,10-phenanthroline 1,10-phenanthroline: RN given refers to parent cpd; inhibits Zn-dependent metalloproteinases	2.01	1	0	phenanthroline	EC 2.7.1.1 (hexokinase) inhibitor; EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor
mercaptoethanol Mercaptoethanol: A water-soluble thiol derived from hydrogen sulfide and ethanol. It is used as a reducing agent for disulfide bonds and to protect sulfhydryl groups from oxidation.	1.97	1	0	alkanethiol; primary alcohol	geroprotector
3-aminobenzamide [no description available]	1.96	1	0	benzamides; substituted aniline	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
acetazolamide Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)	2.05	1	0	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
pimagedine pimagedine: diamine oxidase & nitric oxide synthase inhibitor; an advanced glycosylation end product inhibitor; used in the treatment of diabetic complications; structure. aminoguanidine : A one-carbon compound whose unique structure renders it capable of acting as a derivative of hydrazine, guanidine or formamide.	2.01	1	0	guanidines; one-carbon compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor; EC 1.4.3.4 (monoamine oxidase) inhibitor
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.68	3	0	aromatic ether; nitrile; polyether; tertiary amino compound
erythrosine Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.	2.03	1	0
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	5.47	8	2	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
lidocaine Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.	3.89	2	1	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
ifosfamide [no description available]	2.47	2	0	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic
losartan Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position	2.04	1	0	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist
n-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide: calmodulin antagonist; structure given in first source. N-(4-aminobutyl)-5-chloronaphthalene-2-sulfonamide : A sulfonamide that is 5-chloronaphthalene-2-sulfonamide in which one of the hydrogens of the nitrogen atom is substituted by a 4-aminobutyl group.	1.97	1	0	naphthalenes; organochlorine compound; primary amino compound; sulfonamide
pd 98059 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.	2.02	1	0	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	2.58	2	0	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
rolipram [no description available]	2.05	1	0	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
hydroxyproline Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.. hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.	3.39	7	0	4-hydroxyproline; L-alpha-amino acid zwitterion	human metabolite; mouse metabolite; plant metabolite
spironolactone Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827). spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.	1.99	1	0	3-oxo-Delta(4) steroid; oxaspiro compound; steroid lactone; thioester	aldosterone antagonist; antihypertensive agent; diuretic; environmental contaminant; xenobiotic
aldosterone [no description available]	1.99	1	0	11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde	human metabolite; mouse metabolite
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	2.06	1	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
sucrose Saccharum: A plant genus of the family POACEAE widely cultivated in the tropics for the sweet cane that is processed into sugar.	2.03	1	0	glycosyl glycoside	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; sweetening agent
uridine monophosphate Uridine Monophosphate: 5'-Uridylic acid. A uracil nucleotide containing one phosphate group esterified to the sugar moiety in the 2', 3' or 5' position.. uridine 5'-monophosphate : A pyrimidine ribonucleoside 5'-monophosphate having uracil as the nucleobase.	1.99	1	0	pyrimidine ribonucleoside 5'-monophosphate; uridine 5'-phosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	1.98	1	0	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
triamcinolone acetonide Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.	4.42	2	2	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; cyclic ketal; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
n-vinyl-2-pyrrolidinone N-vinyl-2-pyrrolidinone: monomer of POVIDONE; structure given in first source	2.03	1	0	pyrrolidin-2-ones
styrene Styrene: A colorless, toxic liquid with a strong aromatic odor. It is used to make rubbers, polymers and copolymers, and polystyrene plastics.. styrene : A vinylarene that is benzene carrying a vinyl group. It has been isolated from the benzoin resin produced by Styrax species.	2.01	1	0	styrenes; vinylarene; volatile organic compound	mouse metabolite; mutagen; plant metabolite
1-octene 1-octene: RN given refers to parent cpd. 1-octene : An octene with an unsaturation C-1.	2	1	0	octene
benzoxazoles 1,3-benzoxazole : A benzoxazole in which the benzene ring is fused to a 1,3-oxazole ring across positions 4 and 5.. benzoxazole : Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.	2.13	1	0	1,3-benzoxazoles; mancude organic heterobicyclic parent
thiazoles [no description available]	2	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	3.12	5	0	dialdehyde	biomarker
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	2.01	1	0	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
methylnitrosourea Methylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.. N-methyl-N-nitrosourea : A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by methyl and nitroso groups.	3.36	1	1	N-nitrosoureas	alkylating agent; carcinogenic agent; mutagen; teratogenic agent
bromine Bromine: A halogen with the atomic symbol Br, atomic number 35, and atomic weight 79.904. It is a volatile reddish-brown liquid that gives off suffocating vapors, is corrosive to the skin, and may cause severe gastroenteritis if ingested.	2	1	0	diatomic bromine
chlorine Chlorine: An element with atomic symbol Cl, atomic number 17, and atomic weight 35, and member of the halogen family.	2	1	0	diatomic chlorine; gas molecular entity	bleaching agent
gestrinone Gestrinone: A non-estrogenic contraceptive which is a weak progestin with strong anti-progesterone properties. It is effective if used once a week orally or can also be used in intravaginal devices.	2.05	1	0	oxo steroid
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	4.6	3	2	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
alkenes [no description available]	2	1	0
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.47	2	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	2.44	2	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
epirubicin Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.	2.46	2	0	aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
iopamidol Iopamidol: A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures.. iopamidol : A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a (2S)-2-hydroxypropanamido group at the 5-position.	2.47	2	0	benzenedicarboxamide; organoiodine compound; pentol	environmental contaminant; radioopaque medium; xenobiotic
1,7-phenanthroline [no description available]	2.39	2	0	phenanthroline
at 1258 nitrocaphane: structure	1.96	1	0
perindopril Perindopril: An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure.. perindopril : An alpha-amino acid ester that is the ethyl ester of N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvaline	2.04	1	0	alpha-amino acid ester; dicarboxylic acid monoester; ethyl ester; organic heterobicyclic compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
peroxynitrous acid Peroxynitrous Acid: A potent oxidant synthesized by the cell during its normal metabolism. Peroxynitrite is formed from the reaction of two free radicals, NITRIC OXIDE and the superoxide anion (SUPEROXIDES).	2.01	1	0	nitrogen oxoacid
methotrexate [no description available]	3.76	2	1	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
biotin vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.	2.05	1	0	biotins; vitamin B7	coenzyme; cofactor; Escherichia coli metabolite; fundamental metabolite; human metabolite; mouse metabolite; nutraceutical; prosthetic group; Saccharomyces cerevisiae metabolite
carboplatin [no description available]	3.41	1	1
lycopene [no description available]	2.04	1	0	acyclic carotene	antioxidant; plant metabolite
picibanil Picibanil: A lyophilized preparation of a low-virulence strain (SU) of Streptococcus pyogenes (S. hemolyticus), inactivated by heating with penicillin G. It has been proposed as a noncytotoxic antineoplastic agent because of its immune system-stimulating activity.	4.35	4	1	penicillinate anion
polidocanol Polidocanol: An alkyl polyglycol ether of LAURYL ALCOHOL, chemically defined as an alcohol ethoxylate having an average alkyl chain of 12–14 carbon atoms, and an ethylene oxide chain of 9 ethylene oxide units. It is used as a detergent, and medically as a local anesthetic, and as a sclerosing agent for the treatment of ESOPHAGEAL AND GASTRIC VARICES and VARICOSE VEINS.. polidocanol : A hydroxypolyether that is nonaethylene glycol in which one of the terminal hydroxy functions is substituted by a lauryl (dodecyl) group.	5.58	4	1	hydroxypolyether	hepatotoxic agent; nonionic surfactant; sclerotherapy agent
ginkgolic acid [no description available]	2.05	1	0	hydroxybenzoic acid
sinomenine sinomenine: isolated from root of Sinomenium acutum; antirheumatic, antineuralgic	2.6	1	0	morphinane alkaloid
phosphorus Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.	2.11	1	0	monoatomic phosphorus; nonmetal atom; pnictogen	macronutrient
deglycobleomycin [no description available]	2.01	1	0
peplomycin Peplomycin: An antineoplastic agent derived from BLEOMYCIN.	8.36	1	1	glycopeptide
gadolinium dtpa Gadolinium DTPA: A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see PENTETIC ACID), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)	2.05	1	0	gadolinium coordination entity	MRI contrast agent
tram 39 2-(2-chlorophenyl)-2,2-diphenyl acetonitrile: an intermediate-conductance calcium-activated potassium channel blocker	2.01	1	0
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.11	1	0	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
bleomycin a6 bleomycin A6: forms conjugate with monoclonal antibody anti-CCT2 which binds to leukemia cells	2.25	1	0
oligonucleotides [no description available]	2.89	4	0
hoe 33342 bisbenzimide ethoxide trihydrochloride: benzimidazole fluorescent dye	1.98	1	0
chitosan [no description available]	2.53	2	0
tanshinone ii a sodium sulfonate tanshinone II A sodium sulfonate: has cardioprotective activity; water-soluble derivative of tanshinone II A; isolated from Salvia militiorrhiza; relieves anginal pain; structure	1.98	1	0
cardiovascular agents Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.	2.05	1	0
heparitin sulfate Heparitin Sulfate: A heteropolysaccharide that is similar in structure to HEPARIN. It accumulates in individuals with MUCOPOLYSACCHARIDOSIS.	2.25	1	0
salicylates Salicylates: The salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis.. hydroxybenzoate : Any benzoate derivative carrying a single carboxylate group and at least one hydroxy substituent.. salicylates : Any salt or ester arising from reaction of the carboxy group of salicylic acid, or any ester resulting from the condensation of the phenolic hydroxy group of salicylic acid with an organic acid.. salicylate : A monohydroxybenzoate that is the conjugate base of salicylic acid.	2.05	1	0	monohydroxybenzoate	plant metabolite
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	2.74	3	0
carubicin Carubicin: A very toxic anthracycline-type antineoplastic related to DAUNORUBICIN, obtained from Actinomadura carminata.. carminomycin(1+) : An anthracyline cation that is the conjugate acid of carminomycin, obtained by protonation of the amino group.	4.32	2	2	anthracycline cation
oridonin [no description available]	2.37	2	0
sodium morrhuate Sodium Morrhuate: The sodium salts of the fatty acids in cod liver oil; an irritant and sclerosing agent used to treat varicose veins and arthritic joints.	3.42	1	1
chondroitin sulfates Chondroitin Sulfates: Derivatives of chondroitin which have a sulfate moiety esterified to the galactosamine moiety of chondroitin. Chondroitin sulfate A, or chondroitin 4-sulfate, and chondroitin sulfate C, or chondroitin 6-sulfate, have the sulfate esterified in the 4- and 6-positions, respectively. Chondroitin sulfate B (beta heparin; DERMATAN SULFATE) is a misnomer and this compound is not a true chondroitin sulfate.	2.25	1	0
talisomycin talisomycin: contains components A & B; glycopeptide related to bleomycin antibiotic from actinomycetes strain 6465-94; RN given refers to cpd with unknown MF	1.95	1	0
levoleucovorin Levoleucovorin: A folate analog consisting of the pharmacologically active isomer of LEUCOVORIN.. (6S)-5-formyltetrahydrofolic acid : The pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid.	3.41	1	1	5-formyltetrahydrofolic acid	antineoplastic agent; metabolite
concanavalin a Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.	1.98	1	0
phosphorus radioisotopes Phosphorus Radioisotopes: Unstable isotopes of phosphorus that decay or disintegrate emitting radiation. P atoms with atomic weights 28-34 except 31 are radioactive phosphorus isotopes.	2.11	1	0
phenanthrenes Phenanthrenes: POLYCYCLIC AROMATIC HYDROCARBONS composed of three fused BENZENE rings.. phenanthrenes : Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.	1.98	1	0

Condition	Relationship Strength	Studies	Trials
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.78	10	0
Xanthoma [description not available]	4.18	3	1
Angioma A vascular anomaly due to proliferation of blood or lymphatic vessels that forms a tumor-like mass. Vessels in the angioma may or may not be dilated.	5.47	23	0
Hemangioma A vascular anomaly due to proliferation of BLOOD VESSELS that forms a tumor-like mass. The common types involve CAPILLARIES and VEINS. It can occur anywhere in the body but is most frequently noticed in the SKIN and SUBCUTANEOUS TISSUE. (from Stedman, 27th ed, 2000)	5.47	23	0
Adenocystic Carcinoma [description not available]	2.83	3	0
Carcinoma, Adenoid Cystic Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)	2.83	3	0
Cystic Hygroma Colli [description not available]	2.41	1	0
Lymphatic Abnormalities Congenital or acquired structural abnormalities of the lymphatic system (LYMPHOID TISSUE) including the lymph vessels.	6.65	11	5
Endothelioma, Lymphatic [description not available]	2.43	2	0
Lymphangioma A benign tumor resulting from a congenital malformation of the lymphatic system. Lymphangioendothelioma is a type of lymphangioma in which endothelial cells are the dominant component.	2.43	2	0
Acne [description not available]	2.41	1	0
Cicatrization The formation of fibrous tissue in the place of normal tissue during the process of WOUND HEALING. It includes scar tissue formation occurring in healing internal organs as well as in the skin after surface injuries.	2.41	1	0
Acne Vulgaris A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors.	2.41	1	0
Cicatrix The fibrous tissue that replaces normal tissue during the process of WOUND HEALING.	2.41	1	0
Alveolitis, Fibrosing [description not available]	4.82	32	0
Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.	4.82	32	0
Benign Neoplasms [description not available]	5.54	6	3
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	5.54	6	3
Harelip [description not available]	2.31	1	0
Cancer of Lip [description not available]	2.31	1	0
Cleft Lip Congenital defect in the upper lip where the maxillary prominence fails to merge with the merged medial nasal prominences. It is thought to be caused by faulty migration of the mesoderm in the head region.	2.31	1	0
Ulcer A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.	2.31	1	0
Arteriovenous Malformations Abnormal formation of blood vessels that shunt arterial blood directly into veins without passing through the CAPILLARIES. They usually are crooked, dilated, and with thick vessel walls. A common type is the congenital arteriovenous fistula. The lack of blood flow and oxygen in the capillaries can lead to tissue damage in the affected areas.	3.57	8	0
Cancer of Parotid [description not available]	2.78	3	0
Parotid Neoplasms Tumors or cancer of the PAROTID GLAND.	2.78	3	0
Nasal Polyps Focal accumulations of EDEMA fluid in the NASAL MUCOSA accompanied by HYPERPLASIA of the associated submucosal connective tissue. Polyps may be NEOPLASMS, foci of INFLAMMATION, degenerative lesions, or malformations.	3.35	6	0
B16 Melanoma [description not available]	2.44	2	0
Animal Mammary Carcinoma [description not available]	2.31	1	0
Vascular Malformations A spectrum of congenital, inherited, or acquired abnormalities in BLOOD VESSELS that can adversely affect the normal blood flow in ARTERIES or VEINS. Most are congenital defects such as abnormal communications between blood vessels (fistula), shunting of arterial blood directly into veins bypassing the CAPILLARIES (arteriovenous malformations), formation of large dilated blood blood-filled vessels (cavernous angioma), and swollen capillaries (capillary telangiectases). In rare cases, vascular malformations can result from trauma or diseases.	8.91	29	8
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	2.17	1	0
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	2.17	1	0
Angioma, Cavernous A tumor-like mass with large vascular space that is filled with blood or lymph.	3.91	4	0
Neoplasms, Vascular [description not available]	3.47	1	1
Orbital Neoplasms Neoplasms of the bony orbit and contents except the eyeball.	3.47	1	1
Abnormalities, Maxillofacial [description not available]	5.29	4	3
Recrudescence [description not available]	4.42	4	1
Cyst [description not available]	4.71	3	2
Ear Diseases Pathological processes of the ear, the hearing, and the equilibrium system of the body.	3.47	1	1
Mucocele A retention cyst of the salivary gland, lacrimal sac, paranasal sinuses, appendix, or gallbladder. (Stedman, 26th ed)	2.78	3	0
Salivary Gland Diseases Diseases involving the SALIVARY GLANDS.	2.1	1	0
Cheilitis Granulomatosa [description not available]	2.51	2	0
Hypopharyngeal Cancer [description not available]	2.08	1	0
Cancer of Larynx [description not available]	3.41	7	0
Hypopharyngeal Neoplasms Tumors or cancer of the HYPOPHARYNX.	2.08	1	0
Laryngeal Neoplasms Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.	3.41	7	0
Cancer of Salivary Gland [description not available]	2.48	2	0
Invasiveness, Neoplasm [description not available]	2.78	3	0
Salivary Gland Neoplasms Tumors or cancer of the SALIVARY GLANDS.	2.48	2	0
Degenerative Disc Disease [description not available]	2.55	2	0
Intervertebral Disc Degeneration Degenerative changes in the INTERVERTEBRAL DISC due to aging or structural damage, especially to the vertebral end-plates.	2.55	2	0
Endothelioma, Vascular [description not available]	2.11	1	0
Hemangioendothelioma A neoplasm derived from blood vessels, characterized by numerous prominent endothelial cells that occur singly, in aggregates, and as the lining of congeries of vascular tubes or channels. Hemangioendotheliomas are relatively rare and are of intermediate malignancy (between benign hemangiomas and conventional angiosarcomas). They affect men and women about equally and rarely develop in childhood. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1866)	2.11	1	0
Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.	2.9	4	0
Dermatoses [description not available]	2.13	1	0
Eyelid Diseases Diseases involving the EYELIDS.	3.85	2	1
Skin Diseases Diseases involving the DERMIS or EPIDERMIS.	2.13	1	0
Local Neoplasm Recurrence [description not available]	4.89	4	2
Fibroid [description not available]	2.48	2	0
Cancer of the Uterus [description not available]	2.48	2	0
Leiomyoma A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.	2.48	2	0
Uterine Neoplasms Tumors or cancer of the UTERUS.	2.48	2	0
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	2.47	2	0
Hypertrophy General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).	2.11	1	0
Cancer of Pharynx [description not available]	2.46	2	0
Pharyngeal Neoplasms Tumors or cancer of the PHARYNX.	2.46	2	0
Hepatocellular Carcinoma [description not available]	2.11	1	0
Cancer of Liver [description not available]	2.4	2	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.11	1	0
Liver Neoplasms Tumors or cancer of the LIVER.	2.4	2	0
Female Genital Neoplasms [description not available]	2.15	1	0
Cancer, Embryonal [description not available]	2.47	2	0
Genital Neoplasms, Female Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).	2.15	1	0
Neoplasms, Germ Cell and Embryonal Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.	2.47	2	0
Epulides [description not available]	2.15	1	0
Granulomas [description not available]	2.15	1	0
Gingival Diseases Diseases involving the GINGIVA.	2.15	1	0
Granuloma A relatively small nodular inflammatory lesion containing grouped mononuclear phagocytes, caused by infectious and noninfectious agents.	2.15	1	0
Cancer of Skin [description not available]	6.32	5	1
Skin Neoplasms Tumors or cancer of the SKIN.	6.32	5	1
Postpartum Amenorrhea [description not available]	2.04	1	0
Amenorrhea Absence of menstruation.	2.04	1	0
Atrophy Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.	2.04	1	0
Cancer of Mouth [description not available]	3.75	10	0
Facial Neoplasms New abnormal growth of tissue in the FACE.	2.97	4	0
Mouth Neoplasms Tumors or cancer of the MOUTH.	3.75	10	0
Bleeding [description not available]	2.05	1	0
Hemorrhage Bleeding or escape of blood from a vessel.	2.05	1	0
Congenital Epulides [description not available]	2.05	1	0
Abnormalities, Mouth [description not available]	3.84	2	1
Breast Cancer [description not available]	2.46	2	0
Breast Neoplasms Tumors or cancer of the human BREAST.	2.46	2	0
Carcinoma, Epidermoid [description not available]	6.35	21	2
Cancer of Cervix [description not available]	4.63	6	1
Angiogenesis, Pathologic [description not available]	2.46	2	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	6.35	21	2
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	4.63	6	1
Cryptogenic Fibrosing Alveolitis [description not available]	2.05	1	0
Idiopathic Pulmonary Fibrosis A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.	2.05	1	0
Allergic Reaction [description not available]	2.05	1	0
Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.	2.05	1	0
Cancer of Colon [description not available]	2.05	1	0
Cancer of Testis [description not available]	2.9	4	0
Colonic Neoplasms Tumors or cancer of the COLON.	2.05	1	0
Testicular Neoplasms Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.	2.9	4	0
Verruca [description not available]	3.44	1	1
Foot Dermatoses Skin diseases of the foot, general or unspecified.	3.44	1	1
Warts Benign epidermal proliferations or tumors; some are viral in origin.	3.44	1	1
Pleural Effusion, Malignant Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells.	3.81	2	1
Mouth Ulcer [description not available]	3.44	1	1
Pyrexia [description not available]	3.78	2	1
Fever An abnormal elevation of body temperature, usually as a result of a pathologic process.	3.78	2	1
Oral Ulcer A loss of mucous substance of the mouth showing local excavation of the surface, resulting from the sloughing of inflammatory necrotic tissue. It is the result of a variety of causes, e.g., denture irritation, aphthous stomatitis (STOMATITIS, APHTHOUS); NOMA; necrotizing gingivitis (GINGIVITIS, NECROTIZING ULCERATIVE); TOOTHBRUSHING; and various irritants. (From Jablonski, Dictionary of Dentistry, 1992, p842)	3.44	1	1
Hemangioma, Capillary A dull red, firm, dome-shaped hemangioma, sharply demarcated from surrounding skin, usually located on the head and neck, which grows rapidly and generally undergoes regression and involution without scarring. It is caused by proliferation of immature capillary vessels in active stroma, and is usually present at birth or occurs within the first two or three months of life. (Dorland, 27th ed)	3.83	2	1
Cancer Syndromes, Hereditary [description not available]	2.06	1	0
Ranula A form of retention cyst of the floor of the mouth, usually due to obstruction of the ducts of the submaxillary or sublingual glands, presenting a slowly enlarging painless deep burrowing mucocele of one side of the mouth. It is also called sublingual cyst and sublingual ptyalocele.	2.05	1	0
Chordoma A malignant tumor arising from the embryonic remains of the notochord. It is also called chordocarcinoma, chordoepithelioma, and notochordoma. (Dorland, 27th ed)	3.85	2	1
Cancer of the Tongue [description not available]	2.72	3	0
Tongue Neoplasms Tumors or cancer of the TONGUE.	2.72	3	0
Endometrioma An enlarged area of ENDOMETRIOSIS that resembles a tumor. It is usually found in the OVARY. When it is filled with old blood, it is known as a chocolate cyst.	2.05	1	0
Adenosarcoma A malignant neoplasm arising simultaneously or consecutively in mesodermal tissue and glandular epithelium of the same part. (Stedman, 25th ed)	2.05	1	0
Cancer of the Vagina [description not available]	2.05	1	0
Adenofibroma A benign neoplasm composed of glandular and fibrous tissues, with a relatively large proportion of glands. (Stedman, 25th ed)	2.05	1	0
Endometriosis A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum.	2.05	1	0
Vaginal Neoplasms Tumors or cancer of the VAGINA.	2.05	1	0
Macroglossia The presence of an excessively large tongue, which may be congenital or may develop as a result of a tumor or edema due to obstruction of lymphatic vessels, or it may occur in association with hyperpituitarism or acromegaly. It also may be associated with malocclusion because of pressure of the tongue on the teeth. (From Jablonski, Dictionary of Dentistry, 1992)	2.06	1	0
Carcinoma, Adenosquamous A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.	2.41	2	0
Lymph Node Metastasis [description not available]	4.78	7	1
Maxillary Neoplasms Cancer or tumors of the MAXILLA or upper jaw.	4.1	3	1
Spinal Neoplasms New abnormal growth of tissue in the SPINE.	2.06	1	0
Carcinoma, Mucoepidermoid A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)	2.06	1	0
Adenocarcinoma, Basal Cell [description not available]	3.84	2	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	3.84	2	1
Cancer of Esophagus [description not available]	4.86	4	2
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	4.86	4	2
Microglossia [description not available]	3.47	1	1
Experimental Hepatoma [description not available]	2.45	2	0
Facial Asymmetry Congenital or acquired asymmetry of the face.	3.47	1	1
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	2.42	2	0
Pneumonia Infection of the lung often accompanied by inflammation.	2.42	2	0
Sclerosis A pathological process consisting of hardening or fibrosis of an anatomical structure, often a vessel or a nerve.	2.02	1	0
Arteriosclerosis Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.	2.02	1	0
Symptom Cluster [description not available]	2.02	1	0
Thrombopenia [description not available]	2.02	1	0
Syndrome A characteristic symptom complex.	2.02	1	0
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	2.02	1	0
Cancer of Head [description not available]	4.51	3	0
Malignant Melanoma [description not available]	6.11	4	1
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	4.51	3	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	6.11	4	1
Auricular Cancer [description not available]	2.03	1	0
Ear Neoplasms Tumors or cancer of any part of the hearing and equilibrium system of the body (the EXTERNAL EAR, the MIDDLE EAR, and the INNER EAR).	2.03	1	0
Alopecia Cicatrisata [description not available]	3.41	1	1
Leukocytopenia [description not available]	4.33	2	2
Alopecia Absence of hair from areas where it is normally present.	3.41	1	1
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	4.33	2	2
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	4.61	3	2
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.4	2	0
Mouth Diseases Diseases involving the MOUTH.	2.04	1	0
Cancer of Prostate [description not available]	2.04	1	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.04	1	0
Experimental Neoplasms [description not available]	3.21	6	0
Rhabdomyosarcoma A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)	1.95	1	0
Metaplasia A condition in which there is a change of one adult cell type to another similar adult cell type.	1.95	1	0
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	4.26	4	1
Sarcoma 180 An experimental sarcoma of mice.	3.22	6	0
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	4.26	4	1
Cancer of Lung [description not available]	5.01	5	2
Emesis [description not available]	3.75	2	1
Lung Neoplasms Tumors or cancer of the LUNG.	5.01	5	2
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	3.75	2	1
Granuloma, Hodgkin [description not available]	3.75	2	1
Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.	3.75	2	1
Kaposi Sarcoma [description not available]	3.34	1	1
Diffuse Large B-Cell Lymphoma [description not available]	3.34	1	1
Sarcoma, Kaposi A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause.	3.34	1	1
Lymphoma, Large B-Cell, Diffuse Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.	3.34	1	1
Benign Neoplasms, Brain [description not available]	1.96	1	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	1.96	1	0
Carbon Tetrachloride Poisoning Poisoning that results from ingestion, injection, inhalation, or skin absorption of CARBON TETRACHLORIDE.	1.98	1	0
Focal Segmental Glomerulosclerosis [description not available]	1.98	1	0
Cirrhoses, Experimental Liver [description not available]	1.98	1	0
Glomerulosclerosis, Focal Segmental A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE.	1.98	1	0
Leukemia, Lymphocytic [description not available]	2.67	3	0
Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.	2.67	3	0
Carcinoma, Anaplastic [description not available]	1.98	1	0
Experimental Leukemia [description not available]	2.89	4	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	1.98	1	0
Injuries, Radiation [description not available]	1.97	1	0
Cancer of Nasopharynx [description not available]	1.96	1	0
Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX.	1.96	1	0
Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.	2.37	2	0
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	2.37	2	0
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	2.37	2	0
EHS Tumor [description not available]	1.97	1	0

bleomycetin

Description

Cross-References

Synonyms (1)

Research Excerpts

Toxicity

Compound-Compound Interactions

Bioavailability

Dosage Studied

Research

Studies (255)

Study Types

bleomycetin

Description

Cross-References

Synonyms (1)

Research Excerpts

Toxicity

Compound-Compound Interactions

Bioavailability

Dosage Studied

Research

Studies (255)

Study Types

Related Drugs (82)

Related Conditions (194)